Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy.

Gambichler, Thilo

Paraneoplastic hyperleucocytosis in a melanoma patient after initiation of ipilimumab and nivolumab combination therapy. [electronic resource] - Journal for immunotherapy of cancer 10 2018 - 113 p. digital

Publication Type: Case Reports; Journal Article

2051-1426

10.1186/s40425-018-0430-y doi


Aged
Antineoplastic Agents, Immunological--adverse effects
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Fatal Outcome
Female
Humans
Ipilimumab--adverse effects
Leukocytosis--chemically induced
Melanoma--drug therapy
Nivolumab--adverse effects
Paraneoplastic Syndromes--chemically induced
Skin Neoplasms--drug therapy